InvestorsHub Logo
Followers 971
Posts 383067
Boards Moderated 5
Alias Born 06/24/2011

Re: None

Wednesday, 11/30/2022 9:14:31 AM

Wednesday, November 30, 2022 9:14:31 AM

Post# of 2795
$NBIO is certainly early-stage: its flagship drug is just heading toward Phase 2 clinical research, right in the sweet spot for dealmaking as a potential acquisition target as deals pick up pace this cycle. https://www.marketwatch.com/press-release/fishing-for-bargains-nascent-biotech-otcmktsnbio-ripe-for-acquisition-2022-11-30?reflink=mw_share_twitter
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News